Company news
Abbisko Cayman Limited (HKEX:2256) news
Abbisko Cayman Limited news releases on 6ix. Latest, Oct 2, 2026: Next Day Disclosure Returns
Press releases & updates
Next Day Disclosure Returns
October 2, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 2, 2026
Next Day Disclosure Returns
September 29, 2026
Next Day Disclosure Returns
September 28, 2026
AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
April 21, 2026
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
January 11, 2026
Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
December 22, 2025
Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
June 15, 2025
Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT
June 10, 2025
Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC
May 26, 2025
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress
May 12, 2025
2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1
April 26, 2025
Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib
March 30, 2025
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）
January 7, 2024
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
December 4, 2023
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
July 4, 2022
Abbisko Cayman : Qiming's Portfolio Company Abbisko Lists on Main Board of HKEx
October 14, 2021